Why Did Capricor Therapeutics Stock Skyrocket Today?

The HOPE-3 study, involving 106 participants across 20 U.S. centres, delivered strong signals of benefit for muscle and heart function.

• HOPE-3 was a randomized, double-blind, placebo-controlled trial.
• The trial administered Deramiocel infusions every three months over a 12-month period.

Capricor Therapeutics (CAPR) announced on Wednesday that its experimental cell therapy Deramiocel achieved both its primary and key secondary goals in the pivotal Phase 3 trial for Duchenne muscular dystrophy (DMD). 

The HOPE-3 study, involving 106 participants across 20 U.S. centres, delivered strong signals of benefit for muscle and heart function.

Trial Design And Participants

HOPE-3 was a randomized, double-blind, placebo-controlled trial that administered Deramiocel infusions every three months over a 12-month period. The average age of enrolled boys and young men was around 15, and all continued their standard corticosteroid therapy. 

At baseline, about 90% were on cardiac medications, and over 75% already had clinical cardiomyopathy. Following the study results, Capricor’s stock surged by over 440% on Wednesday morning. 

Get updates to this developing story directly on Stocktwits.<